AZD2461: Novel PARP Inhibitor for Breast Cancer Research

Executive Summary: AZD2461 is a next-generation poly (ADP-ribose) polymerase (PARP) inhibitor with nanomolar potency (IC50 = 5 nM) targeting DNA repair and programmed cell death mechanisms in cancer cells (APExBIO). It induces cytotoxicity and G2 phase cell cycle arrest in MCF-7 and SKBR-3 breast cancer cell lines in a concentration- and time-dependent manner (Schwartz 2022). AZD2461 demonstrates reduced affinity for P-glycoprotein (Pgp), offering potential to overcome multidrug resistance compared to earlier PARP inhibitors. In vivo, AZD2461 efficiently inhibits tumor PARP activity with prolonged relapse-free survival in BRCA1-mutated models. Stability, solubility, and optimized workflow parameters make AZD2461 suitable for advanced breast cancer research and DNA repair pathway studies.

Biological Rationale

Poly (ADP-ribose) polymerase (PARP) enzymes, particularly PARP-1, are integral to cellular DNA repair via the base excision repair (BER) pathway (Schwartz, 2022). Inhibition of PARP disrupts DNA repair, leading to accumulation of DNA breaks and cell death, especially in cancer cells with deficient homologous recombination (HR) pathways such as those harboring BRCA1 mutations. Breast cancer frequently exhibits alterations in DNA repair signaling, making it a key target for PARP inhibitor therapies. Overcoming mechanisms of drug resistance, such as Pgp-mediated efflux, is essential for sustained therapeutic response (see related article); this article extends on those findings by providing explicit workflow and mechanistic detail.

Mechanism of Action of AZD2461

AZD2461 is a small molecule with the chemical name 4-[[4-fluoro-3-(4-methoxypiperidine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one, molecular weight 395.43, and formula C22H22FN3O3 (APExBIO). By inhibiting PARP-1 with an IC50 of 5 nM, AZD2461 impedes the repair of single-strand DNA breaks. This inhibition causes accumulation of DNA damage, leading to cell cycle arrest (notably increasing the proportion of cells in G2 phase while reducing S phase entry) and subsequent apoptosis in susceptible cancer cells. Unique to AZD2461 is its reduced affinity for Pgp, compared to olaparib, which may mitigate efflux-mediated resistance (contrast: provides updated resistance data).

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 activity with a half maximal inhibitory concentration (IC50) of 5 nM in vitro (APExBIO).
• In MCF-7 and SKBR-3 breast cancer cell lines, AZD2461 reduces viable cell numbers in a concentration- (5–50 μM) and time-dependent manner (48–72 hours incubation) (Schwartz 2022).
• Treatment leads to G2 phase cell cycle arrest, with a measurable increase in G2 population and decrease in S phase, assessed by cytometry after 48 hours (Schwartz 2022).
• In vivo mouse studies (KB1P tumor model) show PARP activity is suppressed for several hours post-administration; poly (ADP-ribose) levels return to baseline after 24 hours (Schwartz 2022).
• AZD2461 demonstrates lower affinity for P-glycoprotein (Pgp) compared to olaparib, reducing susceptibility to efflux-mediated resistance (related article).
• Chronic administration in mice is well tolerated and significantly extends median relapse-free survival in BRCA1-mutant tumor models (Schwartz 2022).
• Solubility: insoluble in water; soluble in DMSO (≥16.35 mg/mL) and ethanol (≥45.2 mg/mL with ultrasonic assistance); storage at -20°C is recommended (APExBIO).

Applications, Limits & Misconceptions

AZD2461 is applied in breast cancer research, particularly for dissecting PARP signaling and DNA repair pathway vulnerabilities in both drug-sensitive and resistant models. Its low Pgp binding profile is advantageous in Pgp-overexpressing systems. The compound is useful for in vitro cytotoxicity, cell cycle, and DNA damage response assays, as well as in vivo efficacy and pharmacodynamics studies in BRCA1-mutant and PARP-dependent tumor models.

Common Pitfalls or Misconceptions

• AZD2461 is not water soluble; improper dissolution may affect assay reproducibility.
• Prolonged solution storage (beyond short-term use) leads to compound degradation; always prepare fresh solutions.
• Effective only in PARP-dependent or HR-deficient cancer models; limited impact in HR-proficient or PARP-independent tumors.
• Not a pan-PARP inhibitor: specificity is highest for PARP-1, with lower activity against other PARP isoforms.
• Does not substitute for genetic models of DNA repair deficiency; must be used within the context of validated cell or animal systems.

Workflow Integration & Parameters

AZD2461 from APExBIO (SKU: A4164) is supplied as a solid compound (395.43 Da) and should be stored at -20°C. For experimental use, dissolve in DMSO or ethanol (with sonication if needed). Standard in vitro concentrations range from 5 μM to 50 μM, with incubation periods of 48 to 72 hours in cell culture. Confirm compound integrity by preparing fresh solutions for each experiment. In vivo, dosing regimens must be optimized based on tumor model and pharmacokinetic profile. For enhanced research on DNA repair signaling and drug resistance, AZD2461 is compatible with modern systems biology workflows and high-content imaging platforms. For further details and ordering, refer to the AZD2461 product page.

For advanced systems biology and in vitro evaluation strategies not covered here, see this article; the current dossier updates protocols for BRCA1-mutant and Pgp-resistant models.

Conclusion & Outlook

AZD2461 is a validated, next-generation PARP-1 inhibitor for breast cancer and DNA repair studies. Its distinct profile—potent PARP-1 inhibition, reduced Pgp affinity, and robust in vitro and in vivo efficacy—positions it as a preferred tool for mechanistic and translational research in oncology. Ongoing developments in systems biology and drug resistance models may further extend the utility of AZD2461 in precision cancer research. For a protocol-oriented overview and inter-study comparisons, refer to this reference, which this article extends by focusing on new benchmarks and workflow parameters.